Academy of Physicians
in Clinical Research

Academy of Physicians
in Clinical Research




News from SCRIP

APCR Members can get a free trial to SCRIP and a discount on a SCRIP subscription by contacting John Lezcano from SCRIP directly at the information below. 

John Lezcano
Corporate Account Manager

Pharma intelligence | informa
T: (212) 652-2678
M: (631) 807-4971
John.lezcano@informa.com
pharmaintelligence.informa.com

Korean Gene Therapies On Horizon, But Slow Regulatory Changes A Drag

Wed, 01/23/2019 - 1:28pm

While Korean companies are actively pursuing development of gene therapies, various regulatory restrictions at home are keeping them from speeding...

      Related Stories 

Why Roche Oncology Bet Big On Neoantigen-Directed T-Cell Therapy

Wed, 01/23/2019 - 11:22am

In an interview at J.P. Morgan, Roche's James Sabry explained why it wants to lead the pack in personalized, neoantigen-directed...

      Related Stories 

Entresto Shines Brightly Among New Launches In India

Wed, 01/23/2019 - 8:16am

Novartis’ Entresto has had a strong run in India, with two second brands in tow, while itraconazole and azilsartan therapies...

      Related Stories 

DATA: Follow The Money, An Interactive Biotech Financing Map

Wed, 01/23/2019 - 8:04am

In 2018, while biotech venture activity spoke mainly with an American accent, China emerged as the world’s third most active...

      Related Stories 

Innovation The Centerpiece In Mixed Japan 2019 Outlook

Tue, 01/22/2019 - 7:06pm

2019 has already brought one industry-shaking event in Japan with the formal completion of the Takeda-Shire deal. But how will...

      Related Stories 

Aurinia’s Voclosporin Misses Superior Tolerability Vs. Restasis, But Pushes On In Dry Eye

Tue, 01/22/2019 - 12:43pm

Aurinia's voclosporin missed the primary endpoint of superior tolerability compared to Restasis, but hit objective secondary efficacy endpoints that that...

      Related Stories 

Aurinia’s Voclosporin Misses Superior Tolerability Vs. Restasis, But Pushes On In Drug Eye

Tue, 01/22/2019 - 12:43pm

Aurinia's voclosporin missed the primary endpoint of superior tolerability compared to Restasis, but hit objective secondary efficacy endpoints that that...

      Related Stories 

J&J Expects Persistent Pricing Pressure Into 2019

Tue, 01/22/2019 - 12:12pm

CEO Alex Gorsky highlighted growing public concern over US drug costs during J&J's Q4 earnings call, pressing for more transparency...

      Related Stories 

TaiwanJ To Progress Liver Drug JKB-122 In AIH After Good Phase II Data

Tue, 01/22/2019 - 7:28am

Taiwanese speciality pharma TaiwanJ said its Phase II orphan drug designation study of investigational therapy JKB-122 in autoimmune hepatitis met...

      Related Stories 

Full Steam Ahead At Ferring To Unlock Microbiome Potential For Reproduction

Tue, 01/22/2019 - 7:13am

The Swiss group is expanding its alliance with the Karolinska Institutet to conduct 10 studies designed to improve understanding of...

      Related Stories 

Sun Firefights Governance Concerns

Tue, 01/22/2019 - 5:18am

Sun has promised to implement certain changes to address corporate governance concerns that have riled investors, including “unwinding” a loan...

      Related Stories 

Revamped Redx’s New CEO Says Porcupine Inhibitor Trials 'Now On Track'

Mon, 01/21/2019 - 9:31am

After regulatory talks, revamped Redx gets green light to resume clinical study of RXC004 in patients with advanced solid tumors...

      Related Stories 

GSK Looks For New Chair To Lead It Through New Strategic Direction

Mon, 01/21/2019 - 6:16am

GSK’s non-exec chairman steps down from the UK firm, just a month after announcing a split that will reshape the...

      Related Stories 

Pages